Pulmonary fibrosis is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, leading to reduced lung compliance, impaired gas exchange, and progressive dyspnea.
The FDA has granted orphan drug designation to Nuformix PLC's tranilast lysate candidate for treating idiopathic pulmonary fibrosis. The designation provides regulatory incentives including potential market exclusivity in the US. Nuformix is a London-based developer focused on fibrosis and oncology treatments.
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07782060 |
Feasibility Randomised Controlled Trial Exploring Implementation of the Compassionate Mindful rEsilience pRogram for People With pUlmonaRY Fibrosis: The MERcURY Study |
COMPLETED | NA |
| NCT07761377 |
Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT |
RECRUITING | |
| NCT07722507 |
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis |
NOT_YET_RECRUITING | |
| NCT07627594 |
Safety of Bronchoscopy in Patients With Interstitial Lung Disease |
NOT_YET_RECRUITING | |
| NCT07572383 |
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis |
RECRUITING | PHASE2 |
| NCT07571291 |
DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS |
ACTIVE_NOT_RECRUITING | |
| NCT07570888 |
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination. |
NOT_YET_RECRUITING | PHASE4 |
| NCT07542067 |
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment |
COMPLETED | PHASE1/PHASE2 |
| NCT07464132 |
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases |
RECRUITING | PHASE1/PHASE2 |
| NCT07459205 |
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases |
NOT_YET_RECRUITING |
